Recombinant Human MIP3a protein

MIP-3α (Macrophage Inflammatory Protein-3α), also known as CCL20 (C-C motif chemokine ligand 20), is a small cytokine belonging to the CC chemokine family. It plays a critical role in immune regulation, particularly in recruiting lymphocytes and dendritic cells to inflammatory sites. Discovered in the late 1990s, MIP-3α is encoded by the CCL20 gene in humans and is structurally characterized by four conserved cysteine residues, with the first two adjacent (CC motif). It binds exclusively to the chemokine receptor CCR6. a G-protein-coupled receptor expressed on immune cells like immature dendritic cells, memory T cells, and B cells.

Biologically, MIP-3α is produced by epithelial cells, macrophages, and dendritic cells in response to pro-inflammatory stimuli such as TNF-α, IL-1β, or microbial pathogens. It orchestrates immune surveillance by directing CCR6-expressing cells to mucosal surfaces, lymphoid tissues, and sites of infection or injury. This chemokine is pivotal in bridging innate and adaptive immunity, facilitating pathogen clearance, and maintaining tissue homeostasis. Dysregulation of MIP-3α/CCR6 signaling is implicated in chronic inflammatory diseases (e.g., rheumatoid arthritis, psoriasis), autoimmune disorders, and cancer progression.

Recombinant MIP-3α proteins are engineered using expression systems like *E. coli* or mammalian cells, ensuring high purity and bioactivity. These proteins retain the native structure and function, enabling research applications such as *in vitro* leukocyte migration assays, immune cell differentiation studies, and therapeutic exploration. As a research tool, recombinant MIP-3α aids in dissecting chemokine-receptor interactions, inflammatory pathways, and potential drug targets. Its clinical relevance extends to vaccine development and immunotherapy strategies aimed at modulating immune cell trafficking.